kidney
liver
heart
pancrea
lung
small
intestin
transplant
viabl
therapeut
option
patient
endstag
organ
failur
ongo
advanc
surgic
techniqu
immunosuppress
regimen
periop
manag
result
improv
surviv
allograft
recipi
despit
refin
infect
still
contribut
substanti
morbid
mortal
limit
longterm
success
rate
procedur
infect
particularli
problemat
among
transplant
recipi
sever
reason
immunosuppress
regimen
necessari
limit
allograft
reject
weaken
host
immun
respons
exogen
acquir
pathogen
enabl
endogen
reactiv
latent
infect
frequent
medic
care
newli
transplant
patient
expos
potenti
drugresist
pathogen
infect
respiratori
tract
common
could
herald
develop
sever
diseas
larg
constant
contact
environ
uniqu
predispos
respiratori
system
direct
microbi
inocul
moreov
lung
recipi
specif
suffer
mucociliari
dyskinesia
reduc
mechan
clearanc
respiratori
pathogen
result
airway
anastomos
denerv
allograft
help
prevent
occurr
common
opportunist
infect
transplant
recipi
prophylact
strategi
use
despit
effort
emerg
pathogen
continu
pose
uniqu
challeng
clinician
recogn
diagnos
treat
one
use
paradigm
relev
emerg
infect
recipi
transplant
stratifi
microb
categori
first
categori
consist
known
microb
caus
infect
previous
unrecogn
pathogen
caus
human
diseas
categori
includ
known
microb
alreadi
appreci
pathogen
caus
frequent
sever
diseas
third
categori
compris
newli
discov
pathogen
last
categori
grow
apac
larg
part
technolog
advanc
result
diagnosi
differenti
new
microbi
pathogen
articl
describ
organ
respons
emerg
respiratori
infect
transplant
box
nocardia
gramposit
filament
aerob
actinomycet
variabl
acidfast
stain
characterist
among
commonli
report
opportunist
transplant
pulmonari
nocardiosi
infect
rate
rang
largest
case
seri
transplant
describ
infect
common
among
lung
recipi
follow
recipi
heart
intestin
kidney
liver
howev
literatur
review
difficult
systemat
assess
speci
exist
taxonom
classif
fraught
confus
controversi
recent
isol
caus
human
diseas
label
nocardia
asteroid
includ
organ
consider
differ
antimicrobi
suscept
pattern
technolog
advanc
molecular
genotyp
isol
previous
describ
n
asteroid
subspeci
n
asteroid
denot
n
asteroid
complex
includ
nocardia
nova
complex
nocardia
farcinica
nocardia
transvalensi
complex
nocardia
box
abscessu
newli
nocardia
cyriacigeorgica
moreov
addit
speci
emerg
continu
advanc
genotyp
method
clinic
radiograph
nocardi
infect
nonspecif
often
confin
lung
usual
favor
prognosi
pathogen
hematogen
dissemin
case
central
nervou
system
skin
organ
although
much
less
frequent
report
extrapulmonari
extens
infect
almost
alway
fatal
therefor
earli
recognit
prompt
therapi
crucial
illdefin
clinicoradiograph
featur
diagnosi
frequent
delay
nocardia
slow
grow
organ
mean
durat
week
diagnosi
establish
concurr
infect
contamin
microb
overwhelm
growth
nocardia
speci
laboratori
cultur
media
imped
diagnosi
sever
studi
suggest
nocardia
sole
pathogen
uncommon
comparison
nocardi
infect
coisol
cytomegaloviru
aspergillu
opportunist
fungi
given
delay
diagnosi
clinician
low
threshold
institut
therapi
earli
await
cultur
result
trimethoprimsulfamethoxazol
tmpsmx
prophylaxi
pneumocysti
jiroveci
pneumon
wide
thought
afford
protect
nocardia
infect
howev
nocardiosi
occur
patient
receiv
tmpsmx
prophylaxi
convers
highdos
therapi
cur
suggest
prophylaxi
dosag
ineffect
nocardiosi
prevent
indic
reduc
suscept
infect
establish
therapeut
regimen
use
tmpsmx
combin
imipenem
amikacin
thirdgener
cephalosporin
minocyclin
moxifloxacin
linezolid
concern
resist
avoid
recidiv
protract
cours
least
month
immunocompromis
patient
recommend
abscessu
gramposit
rod
classifi
rapidgrow
nontubercul
mycobacteria
ubiquit
present
sewag
drink
water
decay
veget
normal
skin
flora
genotyp
polymeras
chain
reaction
pcr
method
enabl
distinct
subspeci
pathogen
mycobacterium
chelona
abscessu
identifi
frequent
patient
cystic
fibrosi
cf
less
often
other
structur
lung
abnorm
caus
chronic
respiratori
diseas
occasion
among
immunocompromis
host
preval
studi
nontubercul
mycobacterium
isol
sputum
cultur
patient
cf
abscessu
second
mycobacterium
avium
complex
sensit
sputum
cultur
detect
diseas
due
abscessu
low
increas
littl
serial
sputum
sampl
clinicoradiolog
find
nonspecif
complic
underli
structur
lung
diseas
make
diagnosi
elus
infect
confin
lung
patient
cf
dissemin
uncommon
among
immunocompromis
patient
includ
transplant
recipi
usual
portend
poor
prognosi
whether
abscessu
colon
lung
transplant
contraind
unknown
current
guidelin
urg
caution
face
virul
resist
mycobacteria
especi
posit
result
sputum
smear
transplant
reflect
high
airway
mycobacteri
load
allograft
secondarili
colon
microb
persist
proxim
anastomos
predispos
recipi
infect
newli
transplant
lung
treatment
emerg
respiratori
infect
transplant
establish
maintain
serial
smear
neg
transplant
extens
treatment
intraop
postop
success
treatment
abscessu
complex
difficult
patient
clinician
abscessu
isol
resist
antimycobacteri
agent
includ
tetracyclin
fluoroquinolon
sulfonamid
initi
therapi
includ
combin
clarithromycin
amikacin
cefoxitin
carbapenem
pend
sensit
studi
direct
combin
therapi
continu
minimum
month
neg
result
sputum
cultur
avoid
relaps
mainten
suppress
therapi
clarithromycin
aerosol
amikacin
also
suggest
relaps
extend
therapi
occur
toxic
effect
therapi
interact
transplant
medic
limit
adequ
treatment
r
equi
asporogen
nonmotil
pleomorph
gramposit
coccobacilli
oblig
aerob
belong
famili
nocardioform
order
actinomycet
organ
present
soil
thrive
freshwat
marin
habitat
live
intestin
bloodsuck
arthropod
acquir
inhal
soil
direct
inocul
ingest
colon
persontoperson
transmiss
r
equi
first
isol
caus
agent
equin
bronchopneumonia
first
human
infect
r
equi
report
cavitari
pneumonia
patient
autoimmun
hepat
receiv
immunosuppress
therapi
case
report
subsequ
mark
increas
report
case
occur
commensur
human
immunodefici
viru
advanc
cancer
therapi
transplant
case
report
involv
organ
recipi
involv
lung
establish
diagnosi
r
equi
difficult
imag
nonspecif
occasion
normal
identif
r
equi
cultur
proven
difficult
variabl
acidfast
stain
pleomorph
appear
laboratori
media
two
studi
report
r
equi
lung
infect
heart
recipi
initi
misdiagnos
laboratori
cultur
grew
diptheroid
mistaken
contamin
two
case
involv
kidney
pancrea
pancrea
recipi
misdiagnos
tuberculosi
base
acidfast
stain
radiograph
show
upper
lobe
caviti
small
satellit
nodul
perihilar
mass
nonspecif
infiltr
final
diagnosi
confirm
bronchoalveolar
lavag
cultur
prompt
worsen
respiratori
symptom
given
limit
number
case
heterogen
patient
popul
divers
clinic
manifest
standard
treatment
r
equi
infect
exist
howev
success
report
dual
antibiot
therapi
minimum
month
surgic
drainag
complic
case
combin
use
vancomycin
imipenem
aminoglycosid
fluoroquinolon
suggest
empir
regimen
antimicrobi
suscept
isol
known
asid
candida
speci
aspergillu
speci
common
fungal
pathogen
caus
infect
transplant
patient
genu
compris
speci
although
human
pathogen
mortal
invas
aspergillosi
vari
aspergillu
fumigatu
common
caus
diseas
follow
aspergillu
flavu
rare
terreu
aspergillu
niger
aspergillu
nidulan
recent
ustu
terreu
gain
attent
rare
myceli
fungi
respons
fatal
posttranspl
respiratori
infect
primari
mode
acquisit
inhal
environment
microconidia
similar
myceli
fungi
direct
inocul
skin
predispos
factor
includ
prolong
sever
neutropenia
highdos
steroid
treatment
nosocomi
exposur
hospit
undergo
construct
prophylact
use
amphotericin
b
aerosol
primari
respiratori
infect
establish
organ
procliv
dissemin
case
terreu
ustu
infect
describ
last
year
increas
attribut
grow
popul
sever
immunosuppress
patient
better
diagnost
method
among
case
review
pathogen
transplant
recipi
infect
involv
lung
one
case
note
ustu
half
dissemin
third
involv
central
nervou
system
skin
terreu
emerg
next
common
invas
pulmonari
aspergillosi
fumigatu
flavu
clinician
must
possess
index
suspicion
low
threshold
aggress
often
invas
diagnost
procedur
necessari
sampl
mani
instanc
aspergillu
speci
uniqu
histomorpholog
characterist
cultur
isol
facilit
identif
howev
rare
encount
aspergillu
speci
ustu
terreu
readili
identifi
diagnos
growth
cultur
may
also
hinder
concurr
infect
organ
frequent
aspergillu
speci
nearli
half
patient
pcr
analysi
advantag
rapid
diagnosi
definit
speciat
cultur
take
week
earli
antifung
therapi
routin
initi
fungal
pathogen
suspect
presumpt
identifi
howev
strategi
temper
highli
variabl
suscept
terreu
ustu
grow
recognit
ustu
terreu
clinic
import
speci
resist
amphotericin
b
standard
therapi
invas
aspergillu
infect
report
involv
seri
patient
note
patient
ustu
surviv
receiv
voriconazol
combin
caspofungin
although
report
use
antifung
regimen
prophylaxi
empir
therapi
proven
success
unfortun
terreu
infect
difficult
treat
report
success
isol
respiratori
infect
amen
amphotericin
b
itraconazol
surgic
lobectomi
nonneutropen
transplant
recipi
firm
data
treat
ustu
terreu
infect
avail
reflect
multitud
antifung
regimen
use
nonpharmacolog
method
reduct
immunosuppress
local
surgic
debrid
success
adjunct
therapi
overal
howev
treatment
result
disappoint
fusarium
solani
colorless
septat
myceli
fungu
found
soil
increas
frequenc
among
transplant
recipi
portal
entri
unclear
inhal
ingest
direct
inocul
suspect
infect
dissemin
vascular
invas
format
yeastlik
structur
blood
adventiti
sporul
easili
cultur
characterist
fusiform
canoeshap
macroconidia
fusarium
speci
indistinguish
aspergillu
speci
routin
histolog
diagnosi
ultim
requir
speciat
cultur
among
transplant
recipi
report
infect
mostli
occur
hematopoiet
stem
cell
transplant
hsct
recipi
prolong
neutropenia
rare
seen
solid
organ
recipi
notabl
differ
exist
hsct
emerg
respiratori
infect
transplant
organ
recipi
first
fusariosi
hsct
recipi
occur
trimod
distribut
earli
posttranspl
extrem
neutropenia
median
day
transplant
associ
acut
graft
versu
host
diseas
gvhd
receiv
corticosteroid
therapi
year
posttranspl
associ
extens
gvhd
howev
solid
organ
recipi
fusariosi
occur
first
year
transplant
next
hsct
recipi
typic
fungemia
dissemin
fusariosi
wherea
organ
recipi
develop
isol
infect
case
report
solid
organ
recipi
dissemin
other
isol
lung
n
skin
n
local
infect
hsct
recipi
although
much
less
report
includ
septic
arthriti
endophthalm
osteomyel
cystiti
brain
abscess
cutan
necrot
lesion
lung
pneumonia
nonspecif
alveolar
interstiti
infiltr
nodul
caviti
commonli
involv
site
infect
account
hsct
recipi
develop
invas
diseas
last
especi
set
prolong
neutropenia
fusariosi
mortal
rate
hsct
recipi
death
due
fusariosi
seen
organ
recipi
effect
treatment
regimen
fusariosi
transplant
unknown
invari
requir
correct
neutropenia
respons
rate
dissemin
fusariosi
antifung
therapi
disappoint
organ
resist
current
avail
antifung
surgic
resect
local
diseas
combin
topic
antifung
therapi
success
patient
wherea
treatment
amphotericin
b
alon
respons
rate
respons
rate
report
voriconazol
posaconazol
salvag
treatment
amphotericin
b
failur
adjunct
therapi
granulocyt
transfus
granulocyt
colonystimul
factor
shown
benefit
extens
studi
genu
scedosporium
includ
two
import
human
pathogen
apiospermum
prolifican
histor
scedosporium
speci
found
patient
hematolog
malign
destruct
chronic
lung
diseas
cf
scedosporium
speci
second
common
mold
aspergillu
speci
colon
airway
patient
cf
organ
found
ubiquit
soil
sewag
pollut
water
histolog
indistinct
aspergillu
fusarium
myceli
fungi
infect
occur
via
inhal
spore
direct
tissu
inocul
commonli
involv
respiratori
tract
case
dissemin
infect
organ
transplant
recipi
recent
scedosporium
emerg
pathogen
among
grow
immunocompromis
popul
particularli
transplant
recipi
pcr
method
develop
facilit
earli
identif
pathogen
spectrum
diseas
scedosporium
speci
resembl
aspergillosi
howev
notabl
clinic
differ
pathogen
apiospermum
asexu
anamorph
pseudallescheria
boydii
found
throughout
world
wherea
prolifican
geograph
concentr
spain
australia
southern
unit
state
rate
invas
infect
report
case
apiospermum
half
patient
prolifican
addit
mortal
rate
apiospermum
prolifican
infect
rang
respect
respiratori
involv
associ
higher
mortal
scedosporium
infect
report
sinc
bone
marrow
transplant
recipi
recent
solid
organ
transplant
promin
differ
manifest
infect
within
popul
comparison
hsct
solid
organ
recipi
scedosporium
speci
infect
former
like
infect
prolifican
earli
infect
within
day
compar
year
given
solid
organ
recipi
rare
becom
neutropen
hsct
recipi
also
like
develop
fungemia
poorest
respons
therapi
compar
report
rate
fungemia
dissemin
prolifican
notabl
greater
aspergillu
speci
attribut
organ
abil
undergo
adventiti
sporul
unfortun
effect
antifung
therapi
scedosporium
infect
lack
apiospermum
prolifican
resist
amphotericin
b
antifung
apiospermum
may
suscept
newer
triazol
anecdot
regimen
base
prior
success
treat
case
report
use
voriconazol
monotherapi
combin
terbinafin
echinocandin
prolifican
howev
remain
resist
antifung
therapi
shown
reduc
mortal
surgic
excis
recoveri
neutropenia
independ
associ
surviv
prolifican
longterm
itraconazol
treatment
combin
fluconazol
among
patient
structur
abnorm
airway
colon
scedosporium
speci
lower
rate
dissemin
suggest
possibl
role
mainten
therapi
prevent
diseas
progress
human
metapneumoviru
hmpv
nonseg
singlestrand
rna
viru
belong
paramyxovirida
famili
first
describ
netherland
among
children
acut
respiratori
viral
symptom
hmpv
sinc
increasingli
note
worldwid
distribut
among
children
immunocompromis
adult
includ
transplant
recipi
infect
hmpv
mimic
cours
respiratori
syncyti
viru
rsv
spectrum
mild
respiratori
symptom
wheez
sever
bronchiol
pneumonia
symptomat
infect
occur
less
gener
popul
immunocompromis
popul
temper
climat
season
variat
occur
predominantli
late
winter
januari
april
clinic
radiograph
cours
diseas
close
resembl
rsv
infect
diagnosi
consid
rsv
infect
rule
first
case
hmpv
transplant
involv
hsct
recipi
die
within
week
pneumonia
respiratori
failur
sinc
multipl
seri
among
hsct
lung
liver
recipi
publish
one
studi
involv
lung
transplant
recipi
show
associ
detect
replic
hmpv
bronchoalveolar
lavag
specimen
allograft
reject
despit
intensifi
immunosuppress
treat
acut
reject
viral
clearanc
reduc
viral
replic
lower
detect
level
still
achiev
contrast
respiratori
viral
data
particularli
cytomegaloviru
infect
data
show
increas
viral
replic
intensif
immunosuppress
observ
suggest
differ
mechan
viral
clearanc
pathogen
elucid
diagnosi
hmpv
diseas
confound
sever
factor
first
persist
detect
viru
nasopharyng
aspir
report
asymptomat
hsct
lung
recipi
longterm
respiratori
sequela
emerg
respiratori
infect
transplant
persist
infect
patient
note
second
primari
infect
nearli
univers
age
year
necessit
increas
antibodi
titer
seroconvers
establish
diagnosi
adult
third
although
isol
hmpv
standard
cell
cultur
techniqu
definit
method
detect
technic
difficult
viru
grow
effici
tradit
cell
line
use
viral
isol
pcr
wide
use
method
detect
hmpv
larg
limit
research
investig
fourth
although
nasopharyng
aspir
easili
obtain
detect
less
sensit
bronchoalveolar
lavag
specimen
agent
approv
treat
hmpv
immunocompromis
host
close
clinic
correl
rsv
similar
therapi
use
combin
intraven
ribavirin
immunoglobulin
success
treatment
hsct
recipi
intraven
ribavirin
treatment
use
lung
transplant
recipi
isol
respiratori
symptom
progress
system
diseas
shock
despit
inhal
treatment
repeat
bronchoalveolar
lavag
specimen
test
neg
pcr
therapi
discontinu
increas
report
transplant
literatur
hmpv
caus
diseas
would
prudent
includ
hmpv
differenti
diagnosi
respiratori
infect
especi
winter
month
earli
diagnosi
hmpv
infect
may
reduc
injudici
use
antibiot
invas
diagnost
investig
promot
appropri
infect
control
practic
prevent
nosocomi
spread
lymphocyt
choriomening
viru
lcm
rna
arenaviru
serolog
survey
estim
us
popul
infect
remain
asymptomat
mild
selflimit
infect
lcm
immunocompromis
individu
howev
caus
acut
febril
ill
fatal
dissemin
posttranspl
infect
present
acut
nonspecif
febril
ill
often
abdomin
symptom
frequent
progress
sever
ill
diagnosi
made
serolog
test
antilcm
igg
igm
antibodi
isol
viru
blood
cerebr
spinal
fluid
immunohistochem
stain
tissu
specimen
pcr
infect
occur
either
direct
indirect
exposur
aerosol
rat
urin
excrement
common
hous
mous
natur
host
viru
humantohuman
transmiss
also
document
mother
fetu
via
donor
organ
recipi
among
cluster
lcm
transmiss
donor
organ
recipi
die
multisystem
organ
failur
lone
surviv
patient
respond
ribavirin
therapi
reduct
immunosuppress
interestingli
none
donor
respons
transmiss
clinic
sign
infect
none
igg
igm
antibodi
lcm
one
identifi
rodent
exposur
known
treatment
trial
report
ribavirin
use
base
vitro
viral
suscept
effect
therapi
need
reduc
immunosuppress
remain
unclear
diagnosi
lymphocyt
choriomening
difficult
current
assay
detect
lcm
notabl
insensit
frequent
falseneg
test
result
donor
screen
lack
accur
sensit
diagnost
lcm
necessit
rapid
commun
organ
procur
organ
transplant
center
help
identifi
cluster
patient
infect
stem
common
donor
corona
viru
caus
sever
acut
respiratori
syndrom
sar
associ
outbreak
toronto
area
link
index
case
travel
hong
kong
sever
sar
case
diagnos
pcr
bronchoalveolar
lavag
sampl
occur
among
solidorgan
hsct
recipi
case
despit
treatment
ribavirin
reduct
immunosuppress
rapid
fatal
progress
respiratori
failur
ensu
one
allogen
bone
marrow
recipi
survivor
treat
oral
prednisolon
ribavirin
subsequ
risk
stratif
tool
initi
use
donor
screen
sar
base
hospit
exposur
clinic
symptom
imag
studi
contact
histori
develop
modifi
version
later
implement
potenti
recipi
screen
protocol
highlight
need
high
clinic
suspicion
earli
initi
specif
diagnost
test
exist
serolog
test
pcr
method
avail
respiratori
infect
transplant
medicin
continu
pose
signific
obstacl
associ
detriment
effect
morbid
mortal
high
morbid
mortal
observ
emerg
infect
stem
protean
manifest
diseas
delay
diagnosi
well
appropri
diagnost
therapeut
intervent
earli
institut
mainten
antimicrobi
therapi
often
restrict
toxic
interact
necessari
immunosuppress
drug
also
limit
data
effect
antimicrobi
regimen
exist
therapeut
strategi
base
anecdot
experi
despit
introduct
newer
antimicrobi
infect
continu
emerg
especi
among
transplant
recipi
interact
sever
addit
factor
includ
transplant
type
surgic
techniqu
underli
metabol
defect
epidemiolog
exposur
extent
natur
immunosuppress
prior
antimicrobi
use
contribut
develop
infect
technolog
advanc
improv
diagnost
techniqu
modal
defin
new
previous
uncharacter
pathogen
innov
also
enabl
definit
genotyp
distinct
pathogen
formerli
character
exclus
phenotyp
differ
final
transplant
popul
experienc
increas
number
intensif
immunosuppress
regimen
prolong
surviv
clinician
focu
prevent
infect
possibl
consid
broad
ration
rang
caus
infect
patient
present
respiratori
symptom
perform
earli
intervent
procedur
bronchoscopi
bronchoalveolar
lavag
andor
transbronchi
biopsi
surgic
biopsi
clinic
indic
adequ
diagnost
sampl
maintain
awar
potenti
multidrug
resist
